AbbVie (ABBV) announced that the FDA has issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for ABBV-951 for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). This is the second CRL issued for ABBV-951 by the FDA.The latest CRL was based on some observations on inspection of one of AbbVie's third-party manufacturing facilities listed in the NDA. The inspection did not involve ABBV-951 or any other AbbVie drug. The FDA has not requ ...

The most recent trading session ended with AbbVie (ABBV) standing at $170.75, reflecting a -1.15% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.09%. Meanwhile, the Dow lost 0.1%, and the Nasdaq, a tech-heavy index, added 0.16%.Heading into today, shares of the drugmaker had gained 9.98% over the past month, outpacing the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.Investors will be eagerly watching for the per ...

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manufacturing facilitiesThe CRL does not identify any issues related to the safety, efficacy or labeling of ABBV-951, including the device, and does not request that AbbVie conduct additional efficacy or safety trials related to the drug or device-related testingAbbVie continues to work with the FDA to bring ABBV-951 ...

Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true.If you're looking to pump up your passive income stream, there are a handful of high-yield dividend stocks that deserve your attention. AbbVie (ABBV 1.38%), Ares Capital (ARCC 0.44%), and Realty Income (O 0.92%) have what it takes to deliver heaps of dividend payments to your portfolio in the years ahead.Whether you're interested in a high yield up front, rapid payout growth, or a litt ...

With the stock market near all-time highs, I’m looking forward to the next market crash. Yes, I want the stock market to fall and fall hard. Why? Because that is when you can go on a shopping spree. All the great companies that are trading at exceptionally high premiums will be suddenly offering discounts. That is when you want to buy.The last market crash was brought on by the pandemic. The S&P 500 lost one-third of its value in just one month. Ouch! Since then, though, the benchmark index has been nothing ...

Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companies shifted back toward chronic diseases like diabetes, cancer, and heart disease. And while these illnesses are certainly important to treat, particularly in the U.S., they don’t offer the same kind of dynamic growth that vaccine companies experienced at the height of the race to develop the vaccine for Covid. Two ...

NORTH CHICAGO, Ill., June 21, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share. The cash dividend is payable August 15, 2024, to stockholders of record at the close of business on July 15, 2024.Since the company's inception in 2013, AbbVie has increased its dividend by more than 285 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at leas ...

Ms. Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent directorNORTH CHICAGO, Ill., June 20, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the independent directors of the board have selected Roxanne S. Austin as lead independent director, effective July 1, 2024. Ms. Austin succeeds Glenn F. Tilton, who has served as lead independent director since 2013. Mr. Tilton will continue to serve on the AbbVie Board as an independent director."One of AbbVie's great ...

Building a portfolio today can be both easy and difficult. It’s easy because every bit of data you need to make your choices is available 24/7 with a few taps on the screen. Ironically, it’s also difficult for the same reason. With so many datasets to consider and so little time, it’s hard to know which ones really matter. As a dividend growth investor, I try to cut through the noise and find what matters most, which are high-dividend stocks to buy and hold. For that, I like to look at the Dividend Aristocr ...

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures ...